Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cibus, Inc.CLXT · Entity 6658 | Chief Science Officer | January 04, 2021 | January 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cibus, Inc.
Report date January 04, 2021 · Filed January 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-01-04 transaction · row 1
1 source rowRow 1 · 2021-01-04 · Sale · Disposed 2,513 · Balance 0 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2020. F2: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $4.05 to $4.25, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2020.
F2: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $4.05 to $4.25, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 5, 2021 22:11 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 2,513 | $4.13 | $10,387.99 |
DisclosureSEC source: 0001615594-21-000002 · primary_doc.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2020. F2 · price: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $4.05 to $4.25, inclusive. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 22:08 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 5,026 | $4.75 | $23,873.50 |
DisclosureSEC source: 0001615594-20-000077 · primary_doc.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,513 Read SEC document |
| August 04, 2020 Filed Aug 7, 2020 22:26 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 65,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001615594-20-000052 · primary_doc.xml · derivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-08-04 F1 · derivative.exercise_date: Option vests as to 1/3 of the shares on each of the first three anniversaries of the date of the grant. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 17:09 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615594-19-000027 · primary_doc.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,982 F1 · shares: 50,000 Restricted Stock Units with respect to Calyxt Inc. common stock were granted to reporting person on 6/28/2019 and vest as to 15% of the underlying shares on the first anniversary of the Grant Date, as to 10% of the underlying shares on the second anniversary of the Grant Date, and as to 5% of the underlying shares on the last day of each calendar quarter beginning the first full quarter after the second anniversary of the Grant Date. Read SEC document |
| May 13, 2019 Filed May 15, 2019 22:10 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right to Buy) · Derivative | 68,000 | $0.00 Strike: $15.28 | $0.00 |
DisclosureSEC source: 0001127602-19-018609 · form4.xml · derivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2029-05-13 F1 · derivative.exercise_date: The Stock Option was granted on May 13, 2019 and vests 15% on the first anniversary of the grant date and 10% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 45 months (commencing on September 30, 2021). Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 20:26 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-19-016564 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,611 Underlying: Common Stock · 3,750 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on April 7, 2016 and vested 20% on the grant date and 10% on April 7, 2017, with the remainder vesting quarterly in equal installments over the following 42 months, 25% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 20:26 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 3,750 | $16.31 | $61,152.38 |
DisclosureSEC source: 0001127602-19-016564 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.61, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| April 29, 2019 Filed Apr 30, 2019 20:26 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 3,750 | $3.59 | $13,462.50 |
DisclosureSEC source: 0001127602-19-016564 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 23:44 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,977 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-19-008461 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,361 Underlying: Common Stock · 3,977 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014 and vested 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vested quarterly in equal installments thereafter, 15% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 23:44 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 3,977 | $16.00 | $63,632.00 |
DisclosureSEC source: 0001127602-19-008461 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 23:44 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 3,977 | $3.59 | $14,277.43 |
DisclosureSEC source: 0001127602-19-008461 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 22:41 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,087 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-19-003835 · form4.xml · derivative · entry 6 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,083 Underlying: Common Stock · 4,087 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014 and vested 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vested quarterly in equal installments thereafter, 15% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 22:41 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,087 | $13.00 | $53,131.00 |
DisclosureSEC source: 0001127602-19-003835 · form4.xml · nonDerivative · entry 4 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 22:41 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,087 | $3.71 | $15,180.34 |
DisclosureSEC source: 0001127602-19-003835 · form4.xml · nonDerivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 22:41 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-19-003835 · form4.xml · derivative · entry 5 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,170 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014 and vested 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vested quarterly in equal installments thereafter, 15% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 22:41 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $13.00 | $53,079.00 |
DisclosureSEC source: 0001127602-19-003835 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 22:41 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-19-003835 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:16 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-036959 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,253 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:16 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $13.00 | $53,079.00 |
DisclosureSEC source: 0001127602-18-036959 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 21:16 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-18-036959 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 13:59 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-032714 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,336 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 13:59 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $13.00 | $53,079.00 |
DisclosureSEC source: 0001127602-18-032714 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 13:59 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-18-032714 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:04 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-030029 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,419 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:04 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $13.84 | $56,514.44 |
DisclosureSEC source: 0001127602-18-030029 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.72 to $14.11, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:04 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-18-030029 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:09 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-028219 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,338 Underlying: Common Stock · 4,666 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:09 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,666 | $16.00 | $74,656.00 |
DisclosureSEC source: 0001127602-18-028219 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:09 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,666 | $3.59 | $16,750.94 |
DisclosureSEC source: 0001127602-18-028219 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 21:20 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-027365 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,502 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 21:20 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $16.13 | $65,842.05 |
DisclosureSEC source: 0001127602-18-027365 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $15.79 to $16.62, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 21:20 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-18-027365 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 20:58 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-026014 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,004 Underlying: Common Stock · 4,666 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 20:58 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,666 | $17.31 | $80,768.46 |
DisclosureSEC source: 0001127602-18-026014 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.03 to $17.67, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 20:58 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,666 | $3.59 | $16,750.94 |
DisclosureSEC source: 0001127602-18-026014 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 18:22 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-025119 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,585 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 18:22 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $17.48 | $71,372.47 |
DisclosureSEC source: 0001127602-18-025119 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.98, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 18:22 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-18-025119 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| July 20, 2018 Filed Jul 25, 2018 00:20 UTC Amendment | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-023818 · form4a.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,670 Underlying: Common Stock · 4,666 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| July 20, 2018 Filed Jul 25, 2018 00:20 UTC Amendment | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,666 | $17.94 | $83,708.04 |
DisclosureSEC source: 0001127602-18-023818 · form4a.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| July 20, 2018 Filed Jul 25, 2018 00:20 UTC Amendment | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,666 | $3.59 | $16,750.94 |
DisclosureSEC source: 0001127602-18-023818 · form4a.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| July 20, 2018 Filed Jul 25, 2018 00:03 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-023816 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,670 Underlying: Common Stock · 4,666 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| July 20, 2018 Filed Jul 25, 2018 00:03 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,666 | $17.94 | $83,708.04 |
DisclosureSEC source: 0001127602-18-023816 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F1 · security: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| July 20, 2018 Filed Jul 25, 2018 00:03 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,666 | $3.59 | $16,750.94 |
DisclosureSEC source: 0001127602-18-023816 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:08 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-023108 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,668 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:08 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $17.84 | $72,822.35 |
DisclosureSEC source: 0001127602-18-023108 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.75 to $18.16, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 20:08 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-18-023108 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 19:53 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-021750 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,336 Underlying: Common Stock · 4,666 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 19:53 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,666 | $20.56 | $95,909.63 |
DisclosureSEC source: 0001127602-18-021750 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $20.395 to $20.765, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 19:53 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,666 | $3.59 | $16,750.94 |
DisclosureSEC source: 0001127602-18-021750 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.